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Background: Successful programmatic use of anti-malarials faces challenges that are not covered by standard drug
development processes. The development of appropriate pragmatic dosing regimens for low-resource settings or
community-based use is not formally regulated, even though these may alter factors which can substantially affect
individual patient and population level outcome, such as drug exposure, patient adherence and the spread of drug
resistance and can affect a drug’s reputation and its eventual therapeutic lifespan.
Methods: An in silico pharmacological model of anti-malarial drug treatment with the pharmacokinetic/
pharmacodynamic profiles of artemether-lumefantrine (AM-LF, Coartem®) and dihydroartemisinin-piperaquine
(DHA-PPQ, Eurartesim®) was constructed to assess the potential impact of programmatic factors, including regionally
optimized, age-based dosing regimens, poor patient adherence, food effects and drug resistance on treatment
outcome at population level, and compared both drugs’ susceptibility to these factors.
Results: Compared with DHA-PPQ, therapeutic effectiveness of AM-LF seems more robust to factors affecting drug
exposure, such as age- instead of weight-based dosing or poor adherence. The model highlights the sub-optimally
low ratio of DHA:PPQ which, in combination with the narrow therapeutic dose range of PPQ compared to DHA that
drives the weight or age cut-offs, leaves DHA at a high risk of under-dosing.
Conclusion: Pharmacological modelling of real-life scenarios can provide valuable supportive data and highlight
modifiable determinants of therapeutic effectiveness that can help optimize the deployment of anti-malarials in
control programmes.
Keywords: Falciparum malaria, Anti-malarials, Artemisinins, Dosing regimen, Mathematical model,
Pharmacokinetics, Piperaquine, Lumefantrine, Drug resistance, Patient adherence, Medication adherenceBackground
Deploying new anti-malarial drugs is a three-stage
process. Firstly, new drugs are developed through a
research and development (R&D) pipeline (preclinical
phase). Secondly, clinical studies (Phases I to III) demon-
strate that the new drugs are effective and safe under
controlled clinical conditions. Thirdly, the drugs are
deployed under programmatic or real-life circumstances* Correspondence: e.m.hodel@liverpool.ac.uk
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unless otherwise stated.(post-marketing, Phase IV). The current regulatory drug
development process provides limited guidance on the
programmatic deployment of anti-malarials in low-
resource settings and lacks consensus on the evidence
base required to optimize real-life drug delivery. Undoubt-
edly, clinical trials will always remain the gold standard for
experimental validation of drug effectiveness and safety
and no policy-maker would ever solely rely on model pre-
dictions, but, for ethical reasons, certain clinical trials
cannot reasonably be conducted, e g, trials estimating
the effect of known sub-therapeutic doses, leaving an
uncomfortable gap in our knowledge that might be attd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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elling approaches.
Pharmacological drug treatment models can be con-
structed to assess dosing accuracy and impact at patient
and population level and could constitute a strong sup-
port role in the policy decision-making process in regard
to pharmacological aspects. Their potential has been
highlighted both for the development of paediatric for-
mulations for the ‘Essential Medicines List’ [1] and to
analyse the likely effects of drugs on malaria throughout
a global eradication campaign [2]. Accurate simulations
can rapidly investigate the consequences of varied drug
deployment strategies and help identify optimal dosage
levels, frequency and duration. Moreover, they can be
used to investigate real-life situations that cannot be field
tested, such as anticipated sub- or supra-therapeutic dos-
ing in patients around the cut-off points of dosing bands
or the impact of poor patient adherence on treatment
outcome, and the potential lessons for programmatic de-
livery strategies and the associated monitoring and evalu-
ation. Similarly, they can be used to predict susceptibility
to, and efficacy of, anti-malarials at a time of developing
drug tolerance or resistance and its subsequent spread
through the population [3]. Important factors that deter-
mine treatment success in programmatic settings are
linked to drug exposure related to dosing regimens, treat-
ment adherence and drug resistance. Others include drug
quality, drug interactions, poor or erratic absorption and
misdiagnosis [4].
Decades of work on malaria models have resulted in nu-
merous models of its epidemiology, and the genetics of
drug resistance, but fewer than a dozen published models
specifically focus on anti-malarial drug treatment [3,5-13].
Drug treatment models for malaria are based on mathem-
atical pharmacokinetic/pharmacodynamic (PK/PD) models
describing the effect of antimicrobial drugs (recently
reviewed by Czock & Keller [14]). In the case of mal-
aria, these models use differential equations to track
parasite growth (the parasite submodel), the effect of anti-
malarial drugs (the anti-malarial submodel), and changing
drug concentrations (the pharmacokinetic submodel) [14].
The differential equations are then used to describe the
dynamics of a parasite population in the presence of anti-
malarial drug treatment. Existing PK/PD models either
investigate only monotherapy [5-7,9-11], do not model the
artemisinin-based combination therapy (ACT) drug com-
ponents individually [8] or are not able to reliably replicate
the results of clinical trials [12]. None of the PK/PD
models specifically aim to simulate programmatic settings
where, e g, (un-)intended alterations of intake dose or
drug resistance can jeopardize drug effectiveness and
safety. Models to investigate these real-life challenges
are therefore required to address substantial gaps in our
evidence base, and must be able to (i) allow investigationof the effectiveness of several drugs co-administered as
ACT; (ii) allow changes in PK/PD parameters of individual
ACT drug components (e g, increasing resistance, genetic
variation in drug elimination); and, (iii) reliably reproduce
data from clinical trials.
This study presents a novel PK/PD model that inte-
grates two existing models to simulate the real-life
population level effectiveness of artemether-lumefantrine
(AM-LF) and dihydroartemisinin-piperaquine (DHA-PPQ)
against background scenarios of varying age and weight-
based dosing regimens and levels of drug adherence,
some of the many challenges faced when deploying anti-
malarials in programmatic settings.
Methods
In order to predict drug effectiveness at the individual
and population level and to investigate the effects of de-
creased parasite drug susceptibility to treatment and
poor patient adherence an already existing, validated, in
silico simulation of anti-malarial drug action (hereafter
referred to as the ‘original model’) [3,13] was extended.
While the original model simulated treatment outcomes
based on variation in individual patient PK/PD parame-
ters it only assumed each patient received the ‘correct’
mg/kg dose. As one of the main interests of this study
was the comparison of weight- and age-based dosing re-
gional specific weight-for-age tables were integrated to
assign realistic body weights across all ages of the popu-
lation [15]. This allowed simulated patients to vary in
age and weight so that patient dosages (in mg/kg) would
vary according to proposed age-based and weight-based
dosing regimens. The model was implemented in the
statistical software package R version 3.0.1 [16]. A sche-
matic representation of the model targeted at an audience
with a rather non-modelling background is presented in
Figure 1. The following sections are mainly directed at
readers with particular interest in the mathematical and
technical details of the drug treatment model, its calibra-
tion and validation.
Original drug treatment model
This study adapted the validated PK/PD model of
Winter & Hastings [13] which predicts treatment out-
come in adults based on individual human and infection
parameters including (i) varied patient PK, i.e. volume of
distribution and elimination rate, (ii) varied parasite drug
sensitivity (PD), i e, half-maximum inhibitory concentra-
tion (IC50), maximal parasite-killing rate constant and
slope factor, and (iii) varied parasite densities at time
of treatment. The additional absorption and conversion
phases for the artemisinins, and the parameter specific
estimates of variation around a mean as described in
Kay & Hastings [3] were included (Table 1, for details
and references see [13] and supplementary material in [3]).
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Figure 1 Overview showing the original PK/PD model (black boxes), the extension to allow for region specific dosing by weight or age
(green box) and the different treatment scenarios simulated (red boxes). * If artesunate or artemether are given, the model accounts for
their absorption and conversion into the active metabolite dihydroartemisinin (DHA). The model then updates parasite numbers in the next time
step using only the drug with the larger effect, i.e. either the parent drug or DHA.
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CV <50% and log-normally distributed for CV ≥50% [3].
No parameter specific CV estimates could be found for the
first-order rate constant of parasite killing (Vmax) and the
slope factor (n) and so a default CV of 30% was assumed
[13]. For this study the mean volume of distribution (Vd)
for AM was changed from central Vd to the steady-stateTable 1 Anti-malarial drug parameters for artemether-lumefa
(DHA-PPQ) combination therapies
Drug parameter Artemether + lumefantrine
AM DHA
Vd (L/kg) 46.6 (82) 15 (48)
x (/day) 23.98 (68) –
z (/day) 11.97 (65) –
k (/day) – 44.15 (23)
IC50 (mg/L) 0.0023 (79) 0.009 (117)
Vmax 27.6 27.6
n 4 4
The means with associated variation (i e, coefficient of variation, CV) are given in br
Vd: volume of distribution; x: absorption rate constant; z: conversion rate constant;
effect; Vmax: first-order rate constant of parasite killing; n: slope factor.Vd (i.e. central plus peripheral Vd) reported by [17] so sim-
ulations reproduce cure rates from field data for AM
monotherapy [18-20] and AM-LF combination therapy
[21]. The mean Vd for DHA was changed to that reported
by Giao & de Vries [22] to reproduce cure rates from field
data for AM monotherapy [18-20] and AM-LF combin-
ation therapy [21]. The mean Vd for DHA was changed tontrine (AM-LF) and dihydroartemisinin-piperaquine
Dihydroartemisinin + piperaquine
LF DHA PPQ
21 (263) 1.49 (48) 150 (42)
– – –
– – –
0.16 (5) 19.8 (23) 0.03 (54)
0.032 (102) 0.009 (117) 0.088 (30)
3.45 27.6 3.45
4 4 6
ackets.
k: elimination rate constant; IC50: Concentration producing half the desired
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treatment (for details and references see supplementary
material in [3]) to reproduce cure rates from field data for
DHA monotherapy [23] and DHA-PPQ combination ther-
apy in adults and children [24].
The number of parasites present at the start of treat-
ment P0 was chosen randomly from a uniform distribu-
tion of between 1010 and 1012. The mean maximal
parasite growth rate a was equal to 1.15 with a 30% vari-
ation around the mean. Artemisinin derivatives were as-
sumed to share the same mechanism of action and so
used only the derivative that achieves the higher drug ef-
fect on the parasites in a time step were used [3]. All
patients were assumed to be malaria naïve and have no
acquired immunity.
In brief, this pharmacological model uses a standard
differential equation to find a mathematical description
for the rate of change in total parasite growth and death
rates
dP
dt
¼ P⋅ a−f Ið Þ−f Cð Þð Þ ð½1Þ
where P is the number of parasites in the infection, t is
time after treatment (days), a is the parasite growth rate
(per day), f(C) represents the drug-dependent rate of
parasite killing which depends on the drug concen-
tration C, and f(I) the killing resulting from the hosts
background immunity. As anti-malarial drugs are now typ-
ically deployed as combination therapies and as each drug
may affect parasites in its unconverted and/or converted
forms, predicting the changing numbers of parasites re-
quires an expansion of Equation 1
dP
dt
¼ P⋅ a−f Ið Þ−
Xr
d¼1
f Cdð Þ
 !
ð½2Þ
where r is the number of drugs, the drug effect f(Cd) is
the effect of each drug, d. Note that each active entity
was regarded as a distinct ‘drug’. Reasons for not includ-
ing synergism and cross-resistance between drugs in
a combination are discussed in detail elsewhere [13].
For example artemether-lumefantrine (AM-LF) is three
drugs LF, AM (unconverted) and its active metabolite
dihydroartemisinin (DHA). Integrating Equation 2 using
the separation-of-variables technique (for further details
see step-wise transition from Equation 10 to Equation
16 in Kay & Hastings [3]) allows to predict the number
of parasites at any time, t, after treatment with any num-
ber of drugs, as
Pt ¼ P0e a−f Ið Þð Þt
Yr
d¼1
e
−
Z
f Cdð Þ ð½3ÞDetails on how the parameters described in Table 1
were selected and used to calculate f(Cd) of each drug, d,
can be found in [3].
The original model by Winter & Hastings [13] calcu-
lates the parasite numbers every 12 h during the first
7 days to allow for multiple-dose regimens and then
every 24 h. In order to allow for 8-hourly (AM-LF first
day) and 12-hourly dosing the time steps were decreased
to 4 h for the first 7 days, leading to slightly different re-
sults for AM because of the parasite kill versus time pro-
file (i e, Figure S2 in supplementary material in [3]
shows that the concentration of AM is much higher at
4 h than 12 h). As the switch from 12 h to 4 h time steps
for the first 7 days did not significantly alter treatment
outcome, even smaller time steps (e g, 1 h) were not
considered in order to speed up simulations.
The original model was only validated to predict treat-
ment outcome in adults. In order to validate the model
for children maximal concentrations (cmax) and times to
maximal concentration (tmax) were calculated using the
same PK parameters as in adults (Table 1) without allo-
metric scaling for children of the same weight as the
average weight of the respective children included in
studies on AM and its metabolite DHA in combination
with the partner drug LF [3] and piperaquine (PPQ)
when given with DHA [25-28]. Due to the lack of phar-
macokinetic data for DHA given in combination with
PPQ only in children validation of the model for DHA
was not possible. It was therefore assumed DHA con-
centrations when given with PPQ are comparable to
DHA concentrations observed in AM-LF treatment where
DHA is the active metabolite of AM. Overlap of predicted
cmax and tmax and field observations was found to be good
and consequently the same PK parameters for all age
groups were used (Table 1).
Integration of weight-for-age distribution of malaria
endemic regions
Regional, weight-for-age references representative of the
population in malaria-endemic countries in Africa, Asia
and Latin America were integrated. These references were
based on a modelling method recently developed to allow
the generation of statistically robust weight-for-age refer-
ences from multi-source data [29]. The use of these
weight-for-age references allowed to assign realistic
region-specific weights for patients between 6 months and
25 years of age. Each hypothetical individual was assigned
a random age (in monthly increments) between 6 months
and 25 years and a random weight-for-age percentile from
the regional reference. When using weight-based dosing,
sampled individuals below 5 kg were excluded from the
analysis and replaced by a new random sample record.
The weight-for-age references were also used to generate
optimised age-based regimens for AM-LF and DHA-PPQ
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in Table 2. Note that for DHA-PPQ the manufacturer rec-
ommends a weight-based dosing regimen with 6 bands
(the highest band for individuals weighing 75–100 kg).
When employing regional growth reference to optimise
the predicted number of patients receiving doses within
the therapeutic range only 4 or 5 bands are employed.
Sample size and follow-up time
In a pilot analysis the 95% confidence intervals (CIs) of
the percentage of individuals that had cleared the para-
sites were compared by running the models with 10,000
and 1 million individuals. Larger samples had narrower
CIs but the lower and upper boundaries of the CIs dif-
fered by less than 2% points (e g, 91% versus 93%) and it
was therefore decided to sample only 10,000 individuals
in order to decrease computing time. The post-treatment
follow-up duration of 63 days was chosen in accordance
with the WHO recommendation for the minimal post-
treatment follow-up duration for long half-life drugs in
clinical trials [32].
Treatment scenarios
Individuals were either dosed according to regional age-
bands or global weight-bands. Then the performance of
the two dosing strategies was tested in different pro-
grammatic scenarios, such as poor patient adherence to
treatment, the effect of food intake and the impact on
parasite resistance expressed as IC50.
For illustrative purposes two examples of ACT
were chosen: (i) AM-LF which has become the most
widely recommended first-line regimen for the treat-
ment of uncomplicated falciparum malaria in Africa [33],
and, (ii) DHA-PPQ which is being considered a highly
promising drug for global deployment due to its simpleTable 2 The weight- and age-based dosing regimens investig
dihydroartemisinin-piperaquine (DHA-PPQ)
Weight category
Drug Global Africa
AM-LF 5–14 kg1 6 m–3 yrs 6 m–3 yrs
15–24 kg1 4–10 yrs 4–9 yrs
25–34 kg1 11–14 yrs 10–12 yrs
35 + kg1 ≥15 yrs ≥13 yrs
DHA-PPQ 5– < 7 kg3 6 m–2 yrs 6 m–1 yr
7– < 13 kg3 3–9 yrs 2–8 yrs
13– < 24 kg3 10–14 yrs 9–14 yrs
24– < 36 kg3 ≥15 yrs 15–19 yrs
36– < 75 kg3 – ≥20 yrs
75–100 kg3 – –
1As provided in the World Health Organization Guidelines for the treatment of malar
3 as provided by the manufacturer [31]; 4 daily dose for 3 days (at 0 h, 24 h, 48 h).once-a-day dosing and extended post-treatment prophy-
lactic effect [34-38]. The weight- and age-based regimens
used in this publication are presented in Table 1. The
methodology is sufficiently flexible that other proposed
regimens could be evaluated, and compared. It is of note
that a separate modelling approach, which used the same
regional specific weight-for-age tables mentioned above,
has been employed to predict the optimized age-based
regimens for ACT for case management of uncomplicated
malaria [15] that were used in this study. As neither the
manufacturer of Eurartesim®, the only pharmaceutical
DHA-PPQ product that obtained marketing authorization
from a stringent regulatory authority, nor the current
WHO Guidelines for the Treatment of Malaria [30]
give recommendations on global age-based regimens,
Hayes et al. optimized age-banding thresholds for each
drug for each of the three global malaria-endemic re-
gions (Asia, Africa and Latin America) to result in the
highest possible number of individuals receiving a mg/kg
dose within the therapeutic range currently recommended
by WHO [30].
Results
Treatment outcome at 63 days was categorized as either
(i) all parasites cleared (<1 parasite); (ii) parasites still
present but below the microscopic limit of detection
(LoD) of 108 parasites and might subsequently either clear
or recrudesce; (iii) drug failures, ‘recrudescences’ in the
malaria jargon, above LoD; or, (iv) parasites never cleared,
i e, above LoD during entire post-treatment period.
Fully adherent patients
Each individual was assigned a full course of AM-LF
(twice daily over three days at 0, 8, 24, 36, 48 and
60 hours) or DHA-PPQ (once daily over three days at 0,ated for fixed-dose artemether-lumefantrine (AM-LF) and
Age category Number of tablets
Latin America Asia
6 m–2 yrs 6 m–3 yrs 1 × 20/120 mg2
3–7 yrs 4–11 yrs 2 × 20/120 mg2
8–10 yrs 12–14 yrs 3 × 20/120 mg2
≥11 yrs ≥15 yrs 4 × 20/120 mg2
6 m–1 yr 6 m–2 yrs 0.5 × 20/160 mg4
2–6 yrs 3–10 yrs 1 × 20/160 mg4
7–11 yrs 11–15 yrs 1 × 40/320 mg4
12–16 yrs ≥16 yrs 2 × 40/320 mg4
≥17 yrs – 3 × 40/320 mg4
– – 4 × 40/320 mg4
ia [30]. 2twice daily dose for 3 days (at 0 h, 8 h, 24 h, 36 h, 48 h, 60 h);
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The percentage of individuals in each dosing band with
a mg/kg dose below or above the therapeutic dose range
are summarized in Tables 3 and 4. The percentage of in-
dividuals with mg/kg doses below the WHO-defined
therapeutic dose ranges of DHA and PPQ was calculated
for comparison with a recently published pooled analysis
by the WorldWide Antimalarial Resistance Network
(WWARN) on DHA-PPQ dosing [39]. For a global
population the weight-based regimen in our study would
under-dose 44.13% of children under the age of 5 years
with both DHA and PPQ (compared to 14.42% in older
children and adults or 19.89% in the overall population).
Individuals with low DHA-PPQ doses were more likely
to be parasitaemic (i e, showing more than 108 parasite)
at Day 42 (Figure 2).
Cure rates for both treatments were very high across
ages in fully adherent patients (Tables 5 and 6). When it
was assumed that parasites would be fully sensitive to
treatment, the proportion of individuals that cleared all
parasites after treatment with AM-LF was predicted to
be more than 99% regardless of region and dosing regi-
men (Table 5). Parasites in individuals treated with a full
treatment of DHA-PPQ were cleared in about 91% ofTable 3 Percentage of individuals with mg/kg doses below or
1.4–4 mg/kg artemether (AM) and 10–16 mg/kg lumefantrine
Number of
tablets
Age-based dosing regime
Global Africa Asia L
1 × 20/120 mg n 1448 1448 1448
AM below 6.28% 9.32% 4.97%
AM above 0.07% 0.07% 0.21%
LF below 26.66% 31.63% 23.90%
LF above 11.05% 10.64% 11.53%
2 × 20/120 mg n 2781 2403 3216
AM below 2.45% 2.25% 2.52%
AM above 0.22% 0.17% 0.19%
LF below 8.45% 10.78% 8.86%
LF above 26.65% 20.06% 25.40%
3 × 20/120 mg n 1706 1270 1271
AM below 4.98% 1.81% 2.28%
AM above 0.18% 0.00% 0.00%
LF below 13.07% 9.06% 9.76%
LF above 17.76% 15.04% 11.49%
4 × 20/120 mg n 4065 4879 4065
AM below 8.83% 24.78% 2.44%
AM above 0.00% 0.00% 0.00%
LF below 26.17% 57.45% 14.42%
LF above 1.62% 2.46% 2.07%
n: number of individuals in respective dosing band.cases for the age-based dosing regimen and 97% for the
weight-based dosing regimen (Table 6).
Treatment outcome categories for each age group (in
years) were plotted in stacked bar charts (for illustrative
purposes examples from African population are presented).
Age-based dosing regimen for DHA-PPQ (Figure 3)
showed that the percentages of patients cured along the
age groups exhibited a ‘saw-tooth’ pattern, i e, the highest
cure rates could were seen in individuals at the lower cut-
off of each age band and within the same age band cure
rates decreased with increasing age. This reflects the fact
that younger individuals in a band tend to weigh less and
therefore receive a higher mg/kg dose and consequently
have higher chance to fully clear all parasites. Conversely,
individuals towards the upper cut-off in an age-band are
more likely to receive lower mg/kg doses. In older adoles-
cents and adults this trend flattens because once individ-
uals have reached their adult stature, weight is more likely
associated with nutritional status than age.
Adherence scenarios
Various patterns of non-adherence were investigated to
reflect the patterns of non-adherence reported in the lit-
erature [40-43]. These typically involve skipping one orabove the therapeutic dose range (according to [30]) of
(LF) in each weight- and age-based dosing band
n Weight-based dosing regimen
atin America Global Africa Asia Latin America
1063 2135 1848 2204 1455
5.93% 11.94% 11.53% 10.84% 10.45%
0.00% 0.00% 0.00% 0.00% 0.00%
27.85% 46.60% 43.99% 45.78% 43.44%
6.49% 7.35% 8.17% 8.35% 4.74%
2019 2497 2231 2585 1857
1.78% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00%
9.26% 7.13% 7.08% 6.42% 6.89%
21.15% 0.00% 0.00% 0.00% 0.00%
1147 1578 1307 1659 1206
3.05% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00%
10.99% 0.00% 0.00% 0.00% 0.00%
15.69% 0.00% 0.00% 0.00% 0.00%
5771 3790 4614 3552 5482
34.21% 9.55% 26.16% 2.48% 35.94%
0.00% 0.00% 0.00% 0.00% 0.00%
66.14% 28.94% 60.71% 17.23% 69.66%
2.41% 0.00% 0.00% 0.00% 0.00%
Table 4 Percentage of individuals with mg/kg doses below or above the therapeutic dose range (according to [30]) of
2–10 mg/kg dihydroartemisinin (DHA) and 16–26 mg/kg piperaquine (PPQ) in each weight- and age-based dosing band
Number of
tablets
Age-based dosing regimen Weight-based dosing regimen
Global Africa Asia Latin America Global Africa Asia Latin America
0.5 × 20/160 mg n 1037 657 1037 657 99 89 105 35
DHA below 99.04% 98.48% 99.04% 99.85% 100.00% 100.00% 100.00% 100.00%
DHA above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
PPQ below 99.04% 98.48% 99.04% 99.85% 100.00% 100.00% 100.00% 100.00%
PPQ above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
1 × 20/160 mg n 2836 2825 3222 2037 1343 1204 1401 1003
DHA below 98.55% 95.72% 98.70% 98.63% 59.20% 57.97% 59.31% 61.32%
DHA above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
PPQ below 98.55% 95.72% 98.70% 98.63% 59.20% 57.97% 59.31% 61.32%
PPQ above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
1 × 40/320 mg n 2005 2396 2053 1973 2946 2499 3063 2106
DHA below 87.23% 94.49% 93.18% 93.82% 29.33% 32.53% 28.73% 31.43%
DHA above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
PPQ below 87.23% 94.49% 93.18% 93.82% 29.33% 32.53% 28.73% 31.43%
PPQ above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
2 × 40/320 mg n 4122 2104 3688 2054 1908 1606 1990 1462
DHA below 64.07% 86.98% 60.93% 77.07% 0.00% 0.00% 0.00% 0.00%
DHA above 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
PPQ below 64.07% 86.98% 60.93% 77.07% 0.00% 0.00% 0.00% 0.00%
PPQ above 0.05% 0.00% 0.00% 0.15% 5.56% 6.79% 5.48% 5.54%
3 × 40/320 mg n 0 2018 0 3279 3686 4491 3441 5174
DHA below – 31.27% – 39.92% 6.27% 16.90% 1.08% 24.70%
DHA above – 0.00% – 0.00% 0.00% 0.00% 0.00% 0.00%
PPQ below – 31.27% – 39.92% 6.27% 16.90% 1.08% 24.70%
PPQ above – 0.05% – 0.00% 5.18% 2.58% 6.02% 2.11%
4 × 40/320 mg n 0 0 0 0 18 111 0 220
DHA below – – – – 0.00% 48.65% – 45.00%
DHA above – – – – 0.00% 0.00% – 0.00%
PPQ below – – – – 0.00% 48.65% – 45.00%
PPQ above – – – – 0.00% 0.00% – 0.00%
n: number of individuals in respective dosing band.
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http://www.malariajournal.com/content/13/1/138several doses. The scenarios investigated for AM-LF
were (i) skipping the fifth and/or the sixth doses(s)
(ii) skipping the third to sixth dose inclusive. The scenar-
ios for DHA-PPQ were skipping the second and/or third
dose. Cure rates for AM-LF stayed as high as 99% when
at least four doses were given regardless of region
(Table 5) and only a reduction of the total dose to one
third reduced cure rates to around 95%. For the age-base
dosing regimen of DHA-PPQ cure rates dropped down
to 70% when either the second or third dose was skipped
(Figure 4A) and down to around 30% when only a single
dose of DHA-PPQ was administered (Table 6). Theweight-based dosing regimen performed remarkably bet-
ter with cure rates at around 90% when either the second
or third dose was skipped (Figure 4B) or around 50%
when only a single dose of DHA-PPQ was administered
(Table 6).
Results suggest that AM-LF is less susceptible to non-
adherence than DHA-PPQ. Skipping one or two days of
treatment of DHA-PPQ (equivalent to one or two doses,
respectively) affected treatment outcome to a much greater
extent than skipping one or two days of treatment of
AM-LF (equivalent to two or four doses, respectively).
Skipping the last day of AM-LF treatment, resulted in very
Figure 2 Predicted parasite positivity at Day 3 and 42 in a global population of 10,000 individuals dosed by weight with
dihydroartemisinin-piperaquine (DHA-PPQ). Panels show predicted parasite positivity for DHA and PPQ at Day 3 ((A) and (B), respectively) and
at Day 42 ((C) and (D), respectively). Left of panels: Total numbers of individuals per mg/kg dosing band (white) and individuals that were
parasiaemic (i e, parasite number > 108) (red). Right of panels: Numbers expressed as a percentage.
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http://www.malariajournal.com/content/13/1/138high predicted cure rates, i e, 99%. In contrast, skipping
the last day of DHA-PPQ gave predicted cure rates of 70%
or 90% depending on whether patients were dosed accord-
ing to age or weight, respectively (Tables 5 and 6). If the
last two days (i e, last four doses) of AM-LF were skipped,
cure rates dropped down to around 95%, the threshold that
would lead to a policy change of first-line therapy [44]. In
contrast, skipping the last two days of DHA-PPQ treat-
ment resulted in failure rates of 28% or 50% depending on
whether patients were dosed according to age or weight,
respectively (Tables 5 and 6). Similarly, the saw-tooth pat-
tern observed for the stacked bar charts of cure rates in
every age group became more prominent at lower adher-
ence levels of DHA-PPQ (Figure 4).
Another non-adherence scenario assumed that each
individual ‘forgot’ to take a dose and then continued
with the regular dosing schedule until the full course
was finished on the fourth day. AM-LF was administered
at 0, 8, 36, 48, 60, and 72 hours, i e, the third, fourth,
fifth and sixth dose were delayed by 12 hours. DHA-
PPQ was administered at 0, 48 and 72 hours, resulting
in a delay of the second and third dose by 24 hours. This
delay and the resulting expansion of the treatment dur-
ation to four days did not affect treatment outcome at
day 63 (Tables 5 and 6).
To simulate poor adherence to instructions on food
intake with ACT, a scenario where patients would receive
a full course of AM but only half the respective amount of
LF contained in the coformulated tablet at every doseintake (equivalent to decreased bio-availability by 52% due
to LF intake without fat [45]) was simulated. However, de-
creased bio-availability due to fasting when taking AM-LF
did not affect treatment outcome (Table 5).
Drug resistance scenarios
The impact of resistance on treatment outcome was in-
vestigated by assessing a full course of AM-LF with IC50
values for AM and DHA ten-fold increased and for LF
50-fold increased. These increases in IC50 values were
chosen because previous analyses showed that this
would lead to an increase in drug failure rates to around
10% (Figure 2 in [3]), equal to the threshold recom-
mended by the WHO for a change of treatment regimen
[30]. In the simulations cure rates dropped down to 75%
(Table 5 and Figure 5). The age distribution of treatment
failures when age-based dosing was applied shows that
treatment failure is most likely in individuals at the upper
thresholds of each age-band because they are more likely
to get a lower mg/kg dose.
Time to recrudescence
The time to recrudescence (Tables 7 and 8) seemed
largely consistent for each ACT. Those individuals who
fail treatment with a full course of AM-LF fail early be-
cause the randomly assigned PK/PD parameters do not
allow full clearance of parasites. Those who fail treat-
ment when the total dose of AM-LF is decreased fail ra-
ther late (because the period with drug concentrations
Table 5 Predicted artemether-lumefantrine (AM-LF) treatment outcome (in %) in populations of 10,000 individuals at
63 days follow-up for different treatment scenarios group by dosing regimen (according to Table 2) and geographical
region
Treatment scenario Treatment outcome Age-based dosing regimen Weight-based dosing regimen
Global Africa Asia Latin
America
Global Africa Asia Latin
America
Full course, i e, twice daily over three days at
0, 8, 24, 36, 48 and 60 hours
All parasites cleared 99.83 99.81 99.83 99.81 99.83 99.82 99.85 99.82
Parasites below LoD 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02
Recrudescence 0.15 0.16 0.15 0.16 0.15 0.15 0.13 0.15
Parasites always above LoD 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Fifth dose missed All parasites cleared 99.78 99.75 99.77 99.68 99.79 99.75 99.78 99.68
Parasites below LoD 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02
Recrudescence 0.20 0.22 0.21 0.29 0.19 0.22 0.20 0.29
Parasites always above LoD 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Sixth dose missed All parasites cleared 99.78 99.75 99.77 99.68 99.79 99.75 99.78 99.68
Parasites below LoD 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02
Recrudescence 0.20 0.22 0.21 0.29 0.19 0.22 0.20 0.29
Parasites always above LoD 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Fifth and sixth dose missed All parasites cleared 99.52 99.39 99.55 99.24 99.56 99.4 99.53 99.24
Parasites below LoD 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.02
Recrudescence 0.45 0.58 0.42 0.72 0.41 0.58 0.44 0.72
Parasites always above LoD 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.02
Third, fourth, fifth and sixth dose missed All parasites cleared 95.33 96.56 96.93 96.35 95.07 94.53 95.34 94.21
Parasites below LoD 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.00
Recrudescence 4.50 3.30 2.92 3.48 4.75 5.21 4.50 5.53
Parasites always above LoD 0.16 0.13 0.12 0.15 0.17 0.25 0.15 0.26
Third, fourth, fifth and sixth dose delayed by
12 hours
All parasites cleared 99.83 99.82 99.83 99.81 99.83 99.83 99.85 99.82
Parasites below LoD 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02
Recrudescence 0.15 0.15 0.15 0.16 0.15 0.14 0.13 0.15
Parasites always above LoD 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Increased IC50 by 50-fold for LF and 10-fold
for AM and DHA
All parasites cleared 76.85 73.89 77.62 72.5 75.1 72.99 76.17 71.49
Parasites below LoD 0.02 0.02 0.02 0.00 0.02 0.01 0.01 0.01
Recrudescence 15.49 17.02 15.15 17.7 16.35 17.4 15.72 18.18
Parasites always above LoD 7.64 9.07 7.21 9.80 8.53 9.60 8.10 10.32
Administered without food, i e, 50% lower
dose for LF
All parasites cleared 99.82 99.81 99.83 99.81 99.82 99.8 99.85 99.75
Parasites below LoD 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02
Recrudescence 0.16 0.16 0.15 0.16 0.16 0.16 0.13 0.21
Parasites always above LoD 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02
DHA: dihydroartemisinin; IC50: Concentration producing half the desired effect; LoD: limit of detection (10
8 parasites).
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http://www.malariajournal.com/content/13/1/138above the minimal inhibitory concentration [MIC] is
shorter with an incomplete regimen due to the reduced
area under the drug concentration/time curve [AUC]),
thereby paradoxically increasing the mean time to recru-
descence. The more doses that are missed the shorter
the mean time to recrudescence. There was also a clear
decreased in time to recrudescence for AM-LF when the
IC50 for AM, DHA and LF were increased. For DHA-PPQ,there was a slight decrease in mean time to recrudescence
when the total dose was decreased.
Discussion
This work identified a PK/PD modelling tool that could
support a more standardized approach towards optimiz-
ing the programmatic delivery of anti-malarials based
on weight- or age-bands and exploring their population
Table 6 Predicted dihydroartemisinin-piperaquine (DHA-PPQ) treatment outcome (in %) in populations of 10,000
individuals at 63 days follow-up for different treatment scenarios group by dosing regimen (according to Table 2)
and geographical region
Treatment scenario Treatment outcome Age-based dosing regimen Weight-based dosing regimen
Global Africa Asia Latin
America
Global Africa Asia Latin
America
Full course, i e, once daily over three days at
0, 24 and 48 hours
All parasites cleared 90.53 91.03 90.33 92.21 97.73 97.49 97.78 97.36
Parasites below LoD 0.40 0.47 0.36 0.40 0.41 0.38 0.40 0.46
Recrudescence 8.50 7.93 8.67 6.98 1.82 2.10 1.80 2.11
Parasites always above LoD 0.57 0.57 0.64 0.41 0.04 0.03 0.02 0.07
Second dose missed All parasites cleared 69.24 69.75 68.32 72.70 90.68 89.7 91.06 88.8
Parasites below LoD 0.50 0.55 0.54 0.45 0.52 0.60 0.49 0.65
Recrudescence 24.01 23.73 24.68 21.92 8.13 8.91 7.76 9.59
Parasites always above LoD 6.25 5.97 6.46 4.93 0.67 0.79 0.69 0.96
Third dose missed All parasites cleared 70.46 71.16 69.83 74.02 91.2 90.34 91.61 89.48
Parasites below LoD 0.50 0.50 0.48 0.44 0.48 0.58 0.45 0.62
Recrudescence 24.28 23.76 24.75 22.01 7.77 8.45 7.45 9.16
Parasites always above LoD 4.76 4.58 4.94 3.53 0.55 0.63 0.49 0.74
Second and third dose missed All parasites cleared 27.06 27.64 26.04 30.01 51.90 49.55 52.23 48.77
Parasites below LoD 0.32 0.31 0.32 0.34 0.61 0.47 0.59 0.44
Recrudescence 31.06 31.02 31.37 31.53 31.25 31.91 31.42 31.63
Parasites always above LoD 41.56 41.03 42.27 38.12 16.24 18.07 15.76 19.16
Second and third dose delayed by 24 hours All parasites cleared 89.80 90.18 89.48 91.55 97.62 97.36 97.65 97.19
Parasites below LoD 0.44 0.47 0.41 0.40 0.41 0.40 0.44 0.47
Recrudescence 8.96 8.54 9.29 7.42 1.93 2.20 1.88 2.24
Parasites always above LoD 0.80 0.81 0.82 0.63 0.04 0.04 0.03 0.10
LoD: limit of detection (108 parasites).
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http://www.malariajournal.com/content/13/1/138level performance in real-life settings. To illustrate this
approach, treatment outcome for AM-LF and DHA-
PPQ at population level was compared and the potential
impact of programmatic factors, including regionally op-
timized age-based dosing regimens, poor patient adher-
ence and drug resistance on treatment outcome were
investigated. Predicted cure rates for both treatments
were very high in fully adherent patients. The proportion
of individuals that cleared all parasites after treatment
with AM-LF was predicted to be more than 99% regard-
less of region or assessed dosing regimen provided that
at least the first four of the six doses were taken. This
is in line with a study using a four-dose regimen for
AM-LF [21] that reported high cure rates in an area in
the absence of multidrug-resistant parasites. DHA-PPQ
cure rates in this study were around 97% for the weight-
based dosing regimen in fully adherent patients. This is
consistent with a pooled analysis that reported polymer-
ase chain reaction (PCR)-corrected cure rates of 98.7%
for DHA-PPQ [46]. Thus the basic model seems capable
of reproducing what occurs in controlled settings typical
of clinical studies, increasing confidence in the model’sability to accurately predict the impact of important pro-
grammatic factors (such as poor compliance and the
threat posed by drug resistance) that are more difficult
to quantify and use for direct comparison in the valid-
ation process of the model. Interestingly, results suggest
that the assessed optimized age-based dosing regimens
would achieve similar average cure rates for an entire
population compared to weight-based dosing regimens
in the case of AM-LF but would incur unacceptably high
failure rates of around 10% in the case for DHA-PPQ.
These findings suggest that AM-LF is more robust than
DHA-PPQ in this respect and that the ability of DHA-
PPQ to clear infections is hampered by a suboptimal ra-
tio of DHA:PPQ (1:8 mg) and associated low DHA dose.
In comparison, the AM-LF ratio of 1:5 mg in the fixed-
dose combination exceeds the optimal ratio based on
the WHO recommended target dose of 1:7 mg [30]. A
1:4.5 mg DHA:PPQ ratio might be preferable as this is
the ratio of the WHO recommended target intake doses
for the two components, i e, 4 mg/kg of DHA and
18 mg/kg of PPQ [30]. However, the WHO artemisinin
dose recommendation is based on studies of artesunate
Figure 3 Predicted dihydroartemisinin-piperaquine treatment outcome per age group (in years) in an African population of 10,000
individuals dosed by (A) age or (B) weight (i e, patients receive one dose daily over three days given at 0 h, 24 h and 48 h). Black
triangles indicate the cut-off points of the age-based dosing bands.
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http://www.malariajournal.com/content/13/1/138which has a higher molecular weight than DHA (384.4
versus 284.4 mg/mmol, respectively). Consequently, a
target intake dose of 3 mg/kg DHA would be equivalent
to 4 mg/kg artesunate, suggesting an alternative plaus-
ible 1:6 mg ratio to achieve 3 mg/kg of DHA and
18 mg/kg of PPQ. The narrow therapeutic dose range of
PPQ compared to DHA (16–26 mg/kg versus 2–10 mg/kg
per dose [30], i e, a therapeutic index (TI; the ratio of the
maximum to minimum recommended therapeutic intake
dose in mg/kg) of 1.6 versus 5.0, respectively) means PPQ
drives the weight or age cut-offs in DHA-PPQ regimens,
leaving DHA at a high risk of under-dosing. The average
dose for DHA was 2.5 mg/kg and 19.7 mg/kg for PPQ
(63 and 109% of the recommended target dose [30]) in
10,000 predicted individuals based on the global weight-
for-age distribution. These results are similar to the find-
ings from a pooled analysis by WWARN on DHA-PPQ
where 19.6% of patients received a total dose of DHA
over three days of less than 6 mg/kg (the lower limit for
DHA recommended by the WHO [30]), 20.3% of pa-
tients received less than the WHO recommended lower
limit of PPQ (48 mg/kg total dose over three days). Thecorresponding percentages in the simulation presented
here were 19.89% for each drug. The WWARN analysis
identified that children aged 1–5 years were at greatest
risk of receiving a sub-therapeutic doses compared to all
other age groups [39]. The simulations presented here
also found children under the age of 5 years at particular
high-risk, i e, 44.13% with sub-therapeutic doses. In the
WWARN study the dose of DHA-PPQ was found to be a
significant predictor of parasite positivity on Day 3, and
the dose of PPQ was a significant predictor of recrudes-
cence (Table 6 and Figure 4 in [39]). Individuals with low
DHA-PPQ were, as expected, more likely to have detect-
able parasites (> 108) at Day 42 (n = 182) and the results
obtained here were extremely similar to those reported
in the WWARN study (Figure 2D here versus Figure 4 in
[39], noting that the difference in x-axis scale arises be-
cause Figure 2 here is dose per administration so has to
be multiplied by three for total doses). The one differ-
ence is that predicted failure rates in the simulations be-
came very low at high drug levels whereas the WWARN
tended to plateau off at around 2% even at high drug
dosages. Figure 2 was produced assuming full adherence
Figure 4 Predicted dihydroartemisinin-piperaquine treatment outcome per age group (in years) in an African population of 10,000
individuals dosed by (A) age or (B) weight and last dose skipped (i e, patients receive one dose daily over two days given at 0 h and
24 h). Black triangles indicate the cut-off points of the age-based dosing bands.
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meta-analysis even at high drug dosages due to poor ad-
herence. Due to the low number of individuals with more
than 108 parasites at Day 3 (n = 44), no clear trend in
dose and parasite positivity was found for Day 3.
In practice, full adherence to anti-malarial drug regi-
mens can be less than 50% in ‘real life’ situations [47].
Reasons for non-adherence to anti-malarials are mani-
fold, including adverse events (AEs) [48], rapid clinical
recovery [42,48-52], misunderstanding of instructions
[50,52] and, especially in children, difficulties in adminis-
tration [48,50-52] and fear from over-dosing (‘too many
tablets’) [50,52]. Fixed-dose combinations, user-friendly
packaging and paediatric formulations adopted for newly
developed anti-malarials may help improve adherence, but
a certain level of non-adherence is inevitable and program-
matic deployment policies need to mitigate its impact.
Simulations suggested that delaying a dose did not altertreatment outcome or time of recrudescence (Tables 5, 6, 7
and 8) suggesting that this form of non-adherence does
not threaten drug effectiveness when only a single parasite
population is present. Generally, when the right mg/kg
dose is taken, delaying one dose of the regimen did not
lead to significant levels of failures, whereas decreasing the
total dose did. These results might change in a more com-
plex model of several parasite populations with different
levels of sensitivity to the drug.
A recent study in Papua New Guinea [53] reported
low effectiveness of AM-LF. While this could be ex-
plained by a number of different factors, this study in-
vestigated whether this observation could be simply
due to poor bio-availability of LF if it is not taken
with fatty food. Cure rates for AM-LF remained above
99% even when the bio-availability of LF was de-
creased by around 50%. In this case, the presented
model may be a helpful tool in testing hypotheses on
Figure 5 Predicted artemether-lumefantrine treatment outcome per age group (in years) in an African population of 10,000 individuals
dosed by (A) age or (B) weight when the IC50 of artemether and dihydroartemisinin are 10-fold increased and the IC50 of lumefantrine
is 50-fold increased. Black triangles indicate the cut-off points of the age-based dosing bands.
Hodel et al. Malaria Journal 2014, 13:138 Page 13 of 18
http://www.malariajournal.com/content/13/1/138low effectiveness in clinical trials as it suggests lack of
fatty food may not the reason.
Drug resistance is a long-term concern for all anti-
malarials because it can drastically shorten the anti-
malarials’ therapeutic life-span. While rarely taken into
account, the robustness of a drug and its dosing regimen
against increasing drug tolerance of the parasites should
be considered when deploying new treatment regimens.
The presented modelling tool allows exploring the po-
tential threat posed by drug resistance on treatment out-
come of different drug regimens by simply altering IC50
value of the parasite population. Previous work used the
PK/PD model and allowed patients to acquire new infec-
tions during the course of follow-up (Appendix of [54]).
The model described in this paper could easily be ex-
tended to describe emergence of resistance during ther-
apy by incorporating multiple parasite clones that would
then be selected depending on selection pressure posed
by the drug treatment.
The authors are not dogmatic about the exact PK/PD
method used to predict cure and note there are varia-
tions on the in silico method; for example, users may
want to use one-hour time steps to track stage specificity,reparameterize the models according to their own local
PK/PD estimates or investigate different putative regi-
mens. Notably, the model does not include acquired host
immunity at present. While this can be incorporated (e g,
[13]) it was omitted at this stage as its calibration relies
on arbitrary parameters. Drugs must be able to reliably
cure patients irrespective of their immune status, so the
absence of assumptions on level of immunity will result
in the most conservative recommendations. Similarly,
further fine-tuning of this method could involve the in-
clusion of differences in PK parameters in specific sub-
groups of the population, such as children and pregnant
women, if available.
In essence, a methodology is described that provides a
more probabilistic approach to optimizing dosing based
on PK/PD modelling to estimate treatment outcome ac-
cording to proposed deployment policies. This tool can
support the development process for ACT with low TIs
(e g, PPQ or mefloquine), where dosing all patients
within the narrow therapeutic dose range will not be
feasible using age-based dosing or weight-based dosing
regimens that only use four dose categories (e g, avoid-
ing use of complex regimens with tablet fractions). In
Table 7 Predicted time to recrudescence (in days) for artemether-lumefantrine (AM-LF) in populations of 10,000
individuals for different treatment scenarios group by dosing regimen (according to Table 2) and geographical region
Treatment scenario Age-based dosing regimen Weight-based dosing regimen
Full course, i e, twice daily over three days at 0, 8, 24, 36, 48
and 60 hours
Min. 14 12 14 11 14 12 14 11
1st Qu. 22 19 24 18 22 19 24 18
Median 29 27 31 28 29 28 30 28
Mean 33 31 34 30 31 31 31 29
3rd Qu. 46 46 48 44 41 43 38 38
Max. 57 53 58 52 57 53 56 52
Fifth dose missed Min. 10 8 10 8 10 8 10 8
1st Qu. 17 14 19 20 17 17 19 20
Median 30 28 30 35 25 28 28 36
Mean 30 30 31 32 30 31 32 33
3rd Qu. 44 45 46 43 46 46 47 43
Max. 54 59 55 57 54 59 57 57
Sixth dose missed Min. 10 8 10 8 10 8 10 8
1st Qu. 17 14 19 20 17 17 19 20
Median 30 28 30 35 25 28 28 36
Mean 30 30 31 32 30 31 32 33
3rd Qu. 44 44 45 43 46 46 46 43
Max. 54 59 55 57 54 59 56 57
Fifth and sixth dose missed Min. 6 5 7 5 6 5 7 5
1st Qu. 25 28 22 27 19 28 22 27
Median 35 38 33 38 37 37 36 38
Mean 33 35 33 36 33 34 33 35
3rd Qu. 43 45 43 45 43 45 44 45
Max. 62 61 62 60 62 61 59 60
Third, fourth, fifth and sixth dose missed Min. 3 5 5 3 3 4 3 3
1st Qu. 19 21 23 21 19 18 18 18
Median 26 30 31 29 25 25 25 24
Mean 27 30 31 30 26 26 26 25
3rd Qu. 34 39 39 38 34 33 34 32
Max. 61 61 63 63 61 63 61 63
Third, fourth, fifth and sixth dose delayed by 12 hours Min. 14 12 14 11 14 12 14 11
1st Qu. 22 19 24 18 22 18 24 18
Median 29 26 31 29 29 27 30 28
Mean 33 30 34 30 32 29 31 29
3rd Qu. 46 40 48 44 41 38 38 38
Max. 57 54 58 52 57 54 56 52
Increased IC50 by 50-fold for LF and 10-fold for AM and DHA Min. 5 5 5 5 5 5 5 5
1st Qu. 15 14 15 14 15 14 14 14
Median 20 20 20 20 20 20 20 20
Mean 21 21 21 20 21 21 21 20
3rd Qu. 27 27 27 26 26 26 26 26
Max. 51 57 51 62 54 57 55 55
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Table 7 Predicted time to recrudescence (in days) for artemether-lumefantrine (AM-LF) in populations of 10,000
individuals for different treatment scenarios group by dosing regimen (according to Table 2) and geographical region
(Continued)
Administered without food, i e, 50% lower dose for LF Min. 11 12 14 11 11 9 12 8
1st Qu. 20 19 24 18 20 19 15 18
Median 25 27 31 28 23 28 24 29
Mean 28 31 34 30 27 29 27 30
3rd Qu. 39 46 48 44 34 40 34 41
Max. 52 53 58 52 52 48 52 49
DHA: dihydroartemisinin; IC50: Concentration producing half the desired effect; Min.: minimum; Qu.: quartile; Max.: maximum.
Table 8 Predicted time to recrudescence (in days) for dihydroartemisinin-piperaquine (DHA-PPQ) in populations of
10,000 individuals for different treatment scenarios group by dosing regimen (according to Table 2) and geographical
region
Treatment scenario Age-based dosing regimen Weight-based dosing regimen
Full course, i e, once daily over three days at 0, 24
and 48 hours
Min. 5 5 5 5 7 6 5 6
1st Qu. 18 17 18 19 25 25 25 26
Median 25 25 26 27 34 34 34 32
Mean 27 27 27 28 36 35 35 33
3rd Qu. 35 35 35 36 47 45 46 41
Max. 63 62 63 63 63 63 63 63
Second dose missed Min. 5 5 5 5 5 5 5 5
1st Qu. 13 14 14 14 21 21 22 21
Median 23 23 22 23 29 29 29 29
Mean 24 24 24 25 31 30 31 30
3rd Qu. 33 32 32 33 40 38 39 37
Max. 63 63 63 63 62 63 63 63
Third dose missed Min. 4 4 4 4 4 4 4 4
1st Qu. 12 13 13 13 21 20 21 20
Median 22 22 21 22 29 29 29 29
Mean 23 23 23 23 30 29 30 29
3rd Qu. 31 31 31 32 39 38 39 37
Max. 63 63 63 63 63 63 63 63
Second and third dose missed Min. 3 3 3 3 3 3 3 3
1st Qu. 7 7 7 7 12 11 12 11
Median 15 15 15 16 21 21 22 21
Mean 19 18 18 19 23 22 23 22
3rd Qu. 28 27 28 28 32 31 32 31
Max. 63 63 63 63 63 63 63 63
Second and third dose delayed by 24 hours Min. 6 6 6 6 7 6 7 8
1st Qu. 18 18 19 20 25 25 24 25
Median 26 27 27 28 34 34 34 33
Mean 27 28 28 29 36 35 35 33
3rd Qu. 35 36 36 37 48 45 47 41
Max. 63 63 63 63 63 63 63 63
Min.: minimum; Qu.: quartile; Max.: maximum.
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http://www.malariajournal.com/content/13/1/138these cases, deployment decisions on appropriate band-
ing of dosing regimens will be a compromise between
optimal dosing accuracy and programmatic feasibility.
This study used simple PK/PD modelling and the pri-
mary intention is to demonstrate a methodological ‘road
map’ capable of addressing important deployment issues.
For example, while the lower therapeutic dose for PPQ
is defined as 16 mg/kg, this does not mean that those re-
ceiving less than 16 mg/kg will inevitably fail treatment
and those receiving 16 mg/kg or above will always be
cured. Someone receiving 15.9 mg/kg is less likely to fail
treatment as someone receiving 10 mg/kg. In reality
many factors determine whether or not a patient fails
treatment and many ‘under-dosed’ individuals will still
be cured because they have relatively drug-sensitive par-
asites or they metabolize drugs slower and maintain high
drug concentrations for longer. The method simply aims
to define and capture this complexity to support the (so far
unregulated) decision-making process to translate the
regulatory mg/kg dosing recommendation to program-
matic dosing based on weight or age bands.
The obvious next step is to get similar nuanced, prob-
abilistic measures for the risk of toxicity at higher dose
exposure. Some AEs are dose-independent and would
occur at a constant rate irrespective of the used dosing
regimen, e g, in a pooled analysis of individual patient
data vomiting or diarrhoea were not correlated with the
mg/kg dose of PPQ [39]. Others are dose-dependent and
correlated with PK factors, such as the total AUC and
the maximum concentration reached (cmax), e g, the
length of the corrected interval between the Q and T
wave in the heart’s electrical cycle is positively correlated
with halofantrine exposure [55], glucose-6-phosphate
dehydrogenase (G6PD) deficiency mediates dose-related
toxicity in primaquine [56] and pruritus in sensitive indi-
viduals is linked to chloroquine levels [57]. It is of note
that the between-subject variability in human PK param-
eters is typically 30–50% [58]. The PK component of the
model estimates factors such as cmax and AUC for each
patient, allowing replacing the arbitrary upper thera-
peutic threshold in mg/kg with a more nuanced predic-
tion based on patients’ individual PK. In practice, this is
hampered by the lack of reliable, standardized safety
data from preclinical and clinical studies. Toxicity data
from preclinical studies is mostly unpublished and only
accessible to the manufacturer and regulatory author-
ities. Furthermore, outside clinical trial settings, the rela-
tionship between dose and individual AEs is rarely
known, reports on accidental over-dosing are scarce,
there are no standardized tools to collect or report safety
data, and the association to dose or dose exposure levels
are rarely reported [59]. If these data were available the
methodology would be able to output the proportion of
patients in a group receiving toxic doses and the likelydegree of their toxicity. For example, this would allow to
estimate that x% of patients had ‘mild’ toxicity (perhaps
defined as <10% above a critical cmax). This would allow
policy makers to review and balance the risks of toxicity
versus drug failure based on PK/PD prediction, particu-
larly for anti-malarials with a narrow TI, where it is un-
avoidable that a substantial proportion of patients will
receive a dose outside the established therapeutic dose
range.
Conclusion
This PK/PD modelling approach is a major methodo-
logical advance in the rational design of programmatic
drug deployment, complementary to the data generated
from clinical trials.
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